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ABSTRACT
Objective To determine the value of monitoring blood
pressure by quantifying the probability that observed
changes in blood pressure reflect true changes.
Design Analysis of blood pressure measurements of
patients in the perindopril protection against recurrent
stroke study (PROGRESS).
SettingRandomisedplacebocontrolledtrialcarriedoutin
172 centres in Asia, Australasia, and Europe.
Participants 1709 patients with history of stroke or
transient ischaemic attack randomised to fixed doses of
perindopril and indapamide.
Measurements Mean of two blood pressure
measurements in patients receiving treatment recorded
to the nearest 2 mm Hg with a standard mercury
sphygmomanometer at baseline and then at
three months, six months, nine months, and 15 months
and then every six months to 33 months.
Results There was no change in the mean blood pressure
of the cohort during the 33 month follow-up. Six months
after blood pressure was stabilised on treatment, if
systolic blood pressure was measured as having
increased by >10 mm Hg, six of those measurements
wouldbefalsepositivesforeverytrueincreaseof≥10mm
Hg. The corresponding value for an increase of 20 mm Hg
was over 200. Values for 5 mm Hg and 10 mm Hg
increases in diastolic blood pressure were 3.5 and 39,
respectively. The likelihood that observed increases in
bloodpressurereflectedtrueincreasesrosewiththetime
between measurements such that the ratio of true
positives to false positives reached parity at 21 months.
Conclusions Usual clinical approaches to the monitoring
of patients taking drugs to lower blood pressure have a
low probability of yielding reliable information about true
changesinbloodpressure.Evidencebasedguidelinesfor
monitoring treatment response are urgently required to
guide clinical practice.
Trial registration Australia and New Zealand Clinical Trial
Registry.
INTRODUCTION
The size of the reduction in blood pressure achieved
with antihypertensive drugs is key to the protection
afforded by theseagents.
1 Clinicians commonly moni-
tor the response of blood pressure to treatment
2 to
ensure maximum benefit for each individual. They
typicallymonitortheirpatients’bloodpressureshortly
afterinitiationoftreatmentandthencontinuemonitor-
ing for the long term. Monitoring strategies are based
on the assumption that measured blood pressure can
beusedtoreliablyidentifytheadequacyorinadequacy
of treatment. Measurements of blood pressure, how-
ever, are rather imprecise because they are prone to
considerable background day to day variability
(“noise”) and this can make it difficult to detect a true
change in blood pressure (“signal”). To be effective,
long term monitoring requires the correct inter-
pretation of measurements as reflecting either noise
or signal. If the impact of noise is not fully appreciated
then the effectiveness of treatments might be wrongly
interpreted, resulting in under or over-treatment.
3-6
Patients established on blood pressure lowering
drugs are monitored long term in anticipation of an
increase in blood pressure in subsequent years. Mon-
itoringisusedtodetectariseinbloodpressureabovea
certain threshold level (typically 140/90 mm Hg) that
acts as a signal warranting re-measurement or adjust-
mentof treatment.Whilean averageincrease in popu-
lation blood pressure over time is well established,
there is probably substantial variability in the size of
the increase between individuals. This variability is
expected to increase over time and, therefore, longer
time intervals between measurements might increase
the effectiveness of monitoring.
Patients on fixed doses of antihypertensive drugs,
such as those in the treatment arms of randomised
trials, provide an opportunity to examine to what
extent the observed variability in blood pressure mea-
surementsin treatedpatientsiscausedby truechanges
inbloodpressure.Westudiedthetreatmentarmofthe
perindopril protection against recurrent stroke study
(PROGRESS) to examine how variability in blood
pressure changes over time and its possible impact on
monitoring strategies. We estimated the proportion of
patients who would be correctly identified as having
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ing intervals of three to 33 months.
METHODS
Details of the PROGRESS trial have been described
previously.
7 We analysed the dual treatment arm, for
which active treatment was a regimen of perindopril
4 mg and indapamide 2.0-2.5 mg daily, using data
from the visit at three months after randomisation
until the three year visit. We restricted analyses to the
active treatment arm because our objective was to
assess long term variability after starting blood pres-
sure lowering treatment. At each visit, recorded
blood pressure was the mean of two measurements
taken five minutes apart with the patient in the seated
position,witheachmeasurementbeingrecordedtothe
nearest 2 mm Hg with a standard mercury sphygmo-
manometer. For the purpose of this analysis, the three
monthvisitafterrandomisationwasfixedasthetimeat
whichapatientwillhaveachievedareductioninblood
pressure as a result of antihypertensive treatment and
thetimeatwhichlongtermmonitoringisinitiated.We
estimatedlongtermchangeinbloodpressurefromthis
baseline measurement from the difference between it
and the subsequent follow-up “observed” blood
pressure measurements at each time point (three
months, six months, nine months, etc).
Theobservedbloodpressureateachfollow-uppoint
comprises an underlying “true” average blood pres-
sure plus the“short term variability” caused by techni-
cal measurement error and short term biological
fluctuations (often called “within person” variability
or simply “measurement error”). We use the term
short term variability to describe fluctuations in
blood pressure over a short time period (such as a few
days or a week
5). Short term variance is the statistical
measure of short term variability. Squaring the stan-
dard deviation (SD) gives the “variance,” which is an
additivemeasureconvenientforcalculatingchangesin
variability.Shorttermvariabilityispartofeachfollow-
up measurement—that is,
[observed follow-up blood pressure] =
[true blood pressure] + [short term variability].
The short term variance can be estimated by halving
the observed variance of the difference between two
measurements made within a short time interval. As a
first approximation, we obtained the short term var-
iance from the difference between the measurements
at six and three months. Because the three month time
delay might incorporate some true long term change,
however, we ultimately estimated the expected short
term variance using the variogram approach
8 (see
appendix 1 on bmj.com).
Observed long term changes in blood pressure will
incorporate the “true” average change in the blood
pressure, twice the short term variability (once for the
initial measurement and once for the subsequent mea-
surement), and the “long term variability”—that is,
[observed change in blood pressure from baseline] =
[true average change in blood pressure] +
[2 x (short term variability) + (long term variability)].
The long term variability is the “between person”
variability caused by individuals’ long term changes
in blood pressure deviating above or below the aver-
agechangeofthegroup.Thelongtermvariancecanbe
estimated from the total observed variance of the dif-
ference in blood pressure measurements from the
baseline to each subsequent time point. The above
equation shows that subtracting twice the short term
variance from the total observed variance of the
change will give an estimate of the long term variance
(see appendix 1 on bmj.com).
Usingthe calculatedchangeinvarianceat eachtime
point, we estimated the proportion of patients whose
assumedtruebaselinesystolicbloodpressureof130or
120 mm Hg would truly increase by 10 or 20 mm Hg
(called true positives) to a threshold of 140 mm Hg or
above while receiving treatment. We also estimated
the proportion of patients who would be observed to
be above the thresholds but who actually had true
blood pressure levels below the threshold (that is,
false positives). We repeated this for an assumed true
baseline diastolic blood pressure of 85 or 80 mm Hg
and used changes in blood pressure of 5 or 10 mm Hg
to reach a threshold of 90 mm Hg or above. For both
Table 1 |Characteristics of participants randomised to dual treatment for hypertension
After start of treatment
(baseline) (n=1709)
Before start of treatment
(n=1770)
Mean (SD) age (years) 63 (9) 63 (9)
No (%) of men 1205 (71) 1243 (70)
Mean (SD) blood pressure (mm Hg):
Systolic 133 (17) 149 (18)
Diastolic 80 (10) 87 (11)
No (%) with hypertension* 341 (20) 948 (54)
No (%) taking other antihypertensive
drug†
678 (41)‡ 1009 (57)
*Systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥90 mm Hg.
†Taking blood pressure lowering drug other than trial drug.
‡On other antihypertensive drugs nine months after start of monitoring. Denominator=1668 patients. Data not
available at start of monitoring.
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Fig 1 | Difference in systolic blood pressure (mm Hg) from
baseline measurement to subsequent measurements over
time to 33 months in those receiving dual treatment
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these assuming no change in mean blood pressure
over the three year period. In sensitivity analyses we
also estimated the true and false positive probabilities
assuming an average 1.0 mm Hg per year increase in
systolic blood pressure and a 0.5 mm Hg per year
increase in diastolic blood pressure.
9 The calculations
assumethatthebaselinevalueandthetruechangewith
time are normally distributed and are independent of
each other. See appendix 1 on bmj.com for full details
of the methods.
Previousresearchhasshowndistributionsofsystolic
bloodpressuretobeskewedtotherightandvariability
tobecorrelatedwithbloodpressurelevels.
510-13There-
fore, we checked the distributions of systolic and dia-
stolic blood pressure for normality and examined
Bland-Altman plots of the difference in the measure-
ments from baseline to three months against the aver-
age of these two measurements. Use of a natural log
transformation normalised distributions of systolic
blood pressure and reduced the correlation between
variability and blood pressure level, and we subse-
quentlyrepeatedanalysesafternaturallogtransforma-
tion of systolic blood pressure measurements.
Because the methods described above assume inde-
pendence between baseline blood pressure and the
true change from baseline blood pressure, we also
repeated the analyses using an approach based on
mixed models, which do not assume independence
between baseline level and the true change from base-
line level.
RESULTS
Baseline characteristics
Detailed characteristics of the participants at enrol-
ment have been described previously,
14 but table 1
summarises demographic and blood pressure charac-
teristics relevant to this study. About 38% (n=1357) of
patients at randomisation were recruited in Asian
countries (China or Japan) and the remainder in Aus-
tralasia and Europe. At three months after randomisa-
tion, blood pressure measurements were available for
1709 study participants receiving dual active treat-
ment. At 33 months of follow-up, more than 93%
(1591) of these individuals had blood pressure mea-
surements recorded.
At baseline visit (three months after randomisation
to active combination treatment with an angiotensin
convertingenzyme(ACE)inhibitorandadiuretic)par-
ticipants had an average systolic blood pressure of 133
(SD 17)mmHgand diastolicbloodpressureof 80(SD
10) mm Hg. Blood pressure had decreased on average
16 mm Hg and 7 mm Hg, respectively, from that
recorded before treatment started. Over half (58%) of
participants were prescribed an additional anti-
hypertensivedrug(inadditiontoperindoprilandinda-
pamide) at randomisation and 38% at three years’
follow-up.
Follow-up blood pressure and variability
Systolic blood pressure—The mean blood pressure in the
1709 participants did not change substantially during
follow-up (table 2). The variability of the difference
from baseline increased over time, as shown by the
increasing variance (table 2) and the distribution cen-
tiles(fig1).Theshorttermvariancewasestimatedtobe
93.3mmHg
2(thatis,SD9.7mmHg).Longtermvaria-
bilityincreasedoverthe30monthintervalfromanSD
of 3.8 mm Hg at three months to 11.8 mm Hg at
33 months. Appendix 2 on bmj.com shows compar-
able results for analyses based on the logarithm of sys-
tolic blood pressure.
Table 2 |Long term variability of systolic blood pressure for those receiving dual treatment, calculated from difference from
on treatment baseline measurement of 133 mm Hg (SD 17) to each subsequent time point
Time (months) No of patients
Difference from baseline (mm Hg) Long term variance*
(mm Hg2)
Long term SD†
(mm Hg) Mean (95% CI) Variance
3 1670 0.7 (0.01 to 1.37) 200.9 14.4 3.8
61 6 3 8 −0.3 (−1.0 to −0.5) 224.1 37.6 6.1
91 6 4 4 −0.9 (−1.7 to −0.08) 270.8 84.3 9.2
15 1624 −0.4 (−1.2 to 0.4) 283.6 97.0 9.8
21 1612 −0.7 (−1.6 to 0.1) 303.6 117.1 10.8
27 1585 −0.2 (−1.0 to 0.7) 313.3 126.7 11.3
33 1560 −1.3 (−2.2 to −0.4) 325.8 139.3 11.8
*Estimated by subtracting twice short term variance (93.3 mm Hg) from variance of difference.
†Square root of long term variance.
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Fig 2 | Difference in diastolic blood pressure (mm Hg) from
baseline measurement to subsequent measurements over
time to 33 months in those receiving dual treatment
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not change over time (table 3). As for systolic blood
pressure, however, the variability of difference in dia-
stolic blood pressure from baseline increased with the
durationoffollow-up(table 3andfig2).Theshortterm
variance was estimated to be 33.2 mm Hg
2 (that is, SD
5.8 mm Hg). Long term variability increased over the
30monthsfromanSDof2.7mmHgatthreemonthsto
6.6 mm Hg at 33 months.
Probability of observed increases in blood pressure
reflecting true treatment failures
Tables 4 and 5 show the probabilities that a threshold
systolic of 140 mm Hg or diastolic of 90 mm Hg in a
treatedpatientactuallyrepresentsatruefailureoftreat-
ment. Findings are shown for monitoring intervals of
between three and 33 months after the start of treat-
ment.
We estimated the probabilities in table 4 using the
natural log of measurements ofsystolic blood pressure
to normalise the data, assuming no change in the
underlying mean blood pressure of the group and a
true blood pressure of either 120 or 130 mm Hg at
baseline. As such they are the probabilities that an
observedincreaseof10or20mmHgfromatruebase-
line systolic blood pressure is in fact a true increase of
10 or 20 mm Hg. For example, suppose that an
increase of 20 mm Hg in the systolic blood pressure
is considered as a “signal” for altering treatment. A
patient with a baseline measurement of 120 mm Hg
monitored at six months has a 0.02% probability of
the measurement truly reaching 140 mm Hg or
above. However, 3.4% of individuals would record
blood pressure levels of 140 mm Hg or above at six
months,meaningthatforeveryonetruepositiveresult
(that is, a true increase of 20 mm Hg) there would be
more than 200 other individuals who had an apparent
20 mm Hg increase in systolic blood pressure that was
caused solely by measurement error.
Likewise, we estimated the probabilities in table 5
assuming no change in the underlying mean diastolic
blood pressure of the group and a true blood pressure
of either 85 or 90 mm Hg at baseline. They represent
the probability of an observed increase being a true
Table 3 |Long term variability of diastolic blood pressure for those receiving dual treatment; calculated from difference from
on treatment baseline measurement 80 mm Hg (SD 10) to each subsequent time point
Time (months) No of patients
Difference from baseline (mm Hg) Long term variance*
(mm Hg2)
Long term SD†
(mm Hg) Mean (95% CI) Variance
31 6 7 0 0 . 2 ( −0.2 to 0.6) 73.6 7.2 2.7
61 6 3 7 −0.5 (−0.9 to −0.04) 79.7 13.3 3.6
91 6 4 4 −0.9 (−1.3 to −0.4) 90.9 24.5 4.9
15 1623 −0.5 (−1.1 to −0.1) 93.1 26.7 5.1
21 1612 −1.0(−1.5 to −0.5) 101.8 35.4 5.9
27 1584 −1.0 (−1.5 to −0.5) 108.3 41.9 6.5
33 1560 −1.6 (−2.1 to −1.0) 109.9 43.5 6.6
*Estimated by subtracting twice short term variance (33.2 mm Hg) from variance of difference.
‡Square root of long term variance.
Table 4 |Estimated number of true positive and false positive measurements of systolic blood pressure over threshold of
140 mm Hg from on treatment baseline “true” measurement of 120 mm Hg or 130 mm Hg
True baseline measurement and time
interval between on treatment baseline
and follow-up measurements (months)
% of all measurements truly
≥140 mm Hg
“Observed” positive* test as % of all
measurements (true positive+false
positive)
Ratio of false positive
tests to true positive
tests
120 mm Hg
3 0.0000008 2.3 (0.000008+2.3) >1 000 000
6 0.02 3.4 (0.01+3.4) >200
9 1.2 6.0 (0.7+5.3) 7.2
15 1.6 6.6 (1.0+5.5) 5.3
21 2.6 7.5 (1.7+5.8) 3.4
27 3.2 8.0 (2.1+6.0) 2.9
33 3.8 8.6 (2.5+6.1) 2.4
130 mm Hg
3 0.3 16.8 (0.2+16.6) 93
6 4.6 19.0 (2.7+16.3) 6.0
9 13.8 22.7 (9.3+13.5) 1.5
15 15.3 23.4 (10.4+13.0) 1.3
21 17.5 24.5 (12.2+12.2) 1.0
27 18.6 25.0 (13.1+11.9) 0.9
33 19.7 25.6 (14.1+11.5) 0.8
*“Positive” test is increase in blood pressure above threshold.
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surement. Again, by way of example, suppose that an
increaseof10mmHgisconsidereda“signal”foralter-
ingtreatmentinapatientwithatruebaselinemeasure-
ment of 80 mm Hg. If the patient is monitored at six
monthsthereisa0.3%probabilityofthemeasurement
trulyreaching90mmHgorover.Measurementstaken
at this time interval would yield an observed positive
result in 7.2% of individuals, meaning that for every
one true positive result (that is, a true increase of
10mmHg)therewouldbe39individualsfalselyinter-
preted as having a 10 mm Hg increase in diastolic
blood pressure.
Thefindingsintables 4and5werenotsubstantively
different in sensitivity analyses in which we incorpo-
rated small annual rises in average population blood
pressure (1.0 mm Hg per year for systolic and
0.5mmHgperyearfordiastolic).Likewise,inanalyses
basedonmixedmodelswefoundnosubstantialdiffer-
ences in interpretation of the resultant true positive/
false positive tables (tables 4 and 5).
DISCUSSION
It is usual practice for patients on blood pressure low-
eringdrugstohavetheirprescriptionrenewedordrugs
altered on the basis of blood pressure measurements
and clinical review every six months or so.
15-17 Our
results provide little evidence to support the modifica-
tion of blood pressure management on the basis of
measurementsmadeatthisinterval.Ifthetrueontreat-
ment diastolic blood pressure was initially 80 mm Hg
then 5.8% of patientswould be observed threemonths
later to have a ≥10 mm Hg increase to 90 mm Hg or
over.Thiswouldreflectmorethan1000falsepositives
for every true increase, and in nearly all patients in
whom treatment was identified as failing the appar-
ently high blood pressure levels would reflect only
measurement error. If the true on treatment diastolic
blood pressure was 85 mm Hg instead then 21.6% of
patients would be observed to have a ≥5m mH g
increaseto90mmHgorover.Amuchgreaterpropor-
tion of these observations would reflect real increases
inbloodpressurebuttherewouldstillbeabout11false
positives for every true increase.
It is clear from these data that a single careful blood
pressure measurement taken a few months after the
startoftreatmentisnotusefulformonitoring.Thepro-
gressive increase over time in the long term variability
of measurements between individuals means that an
observed change in blood pressure was more likely to
reflectatruechangeinbloodpressurewithanincrease
inthetimebetweenthestartoftreatmentandfollow-up
monitoring. Thiseffect waslargelydriven bythe num-
ber of true positives increasing with the time interval,
while the number of false positives remained fairly
constant. The probability that an apparent increase in
blood pressure was a true increase rather than a false
positive,however,wasstillnotmuchbetterthan50%if
the first monitoring interval was left until nearly two
years after the start of monitoring.
These data suggest that having accurate measure-
ments of blood pressure at intervals longer than every
six months is probably more useful for monitoring
patientsreceivingantihypertensive drugsthanthe cur-
rentpracticeofaclinicmeasurementeverysixmonths.
There are several possible strategies for improving the
effectiveness of monitoring that need careful quantita-
tiveassessment.Thechanceofdetectingtrueincreases
in blood pressure would be increased if an abnormal
measurementwasusedasasignalformakingaseriesof
repeat measurements at short time intervals. Likewise,
having a more accurate estimate of blood pressure at
baseline and follow-up would minimise short term
variability and increase the capacity to separate true
Table 5 |Estimated number of true positive and false positive measurements of diastolic blood pressure over threshold of
90 mm Hg from baseline measurement of 80 or 85 mm Hg
True baseline measurement and time
intervalbetweenontreatmentbaseline
and follow-up measurements (months)
% of all measurements truly
≥90 mm Hg
“Observed” positive* test as % of all
measurements (true positive+false
positive)
Ratio of false positive
tests to true positive
tests
80 mm Hg
3 0.01 5.8 (0.005+5.8) >1000
6 0.3 7.2 (0.2+7.0) 39
9 2.2 9.4 (1.3+8.1) 6.0
15 2.7 9.9 (1.7+8.2) 4.9
21 4.6 11.3 (3.0+8.3) 2.7
27 6.1 12.4 (4.1+8.3) 2.0
33 6.5 12.7 (4.4+8.3) 1.9
85 mm Hg
3 3.1 21.6 (1.8+19.8) 11
6 8.5 23.2 (5.2+18.0) 3.5
9 15.6 25.5 (10.3+15.2) 1.5
15 16.7 26.0 (11.2+14.8) 1.3
21 20.0 27.3 (13.9+13.4) 1.0
27 22.0 28.2 (15.6+12.6) 0.8
33 22.4 28.4 (16.0+12.4) 0.8
*“Positive” test is increase in blood pressure above threshold.
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estimates can be achieved by using calibrated sphyg-
momanometers, taking measurements at set times in
relation to drug treatment, and taking the mean of sev-
eral measurements, perhaps with self monitoring.
18
Alternatively, control charts,
19 which facilitate the
separation of apparently abnormal measurements
from background variability by plotting re-measure-
ments made at shortened time intervals, can achieve
a better interpretation of the true blood pressure for
any one individual.
8
Limitations and strengths
There were several potential limitations to this study.
Firstly, over half of the patients involved were using
blood pressure lowering drugs in addition to the peri-
ndopril-indapamide studied here; this might have
increasedthevariabilityinbloodpressureinthispopu-
lation. Secondly, participants had all had a previous
stroke or a transient ischaemic attack, which might be
associated with a higher variability of blood pressure
than in the general population.
15 That said, the esti-
mated coefficient of variation in diastolic blood pres-
sure in this study (7.2%) is less than has been found in
clinical practice (11.4% to 16.6%),
3 and blood pressure
measurements in a clinical trial such as PROGRESS
are probably less variable than in clinical practice and
lesspronetootherproblemssuchaszerodigitbias.
20If
therewereforanyreasonextralongtermvariabilityin
these patients compared with the general population,
then our estimates of the effectiveness of monitoring
would probably be overestimated. Likewise, we
would expect additional long term variability to have
resulted from participants in this cohort discontinuing
double blind treatment, which would also imply that
wehaveoverestimatedratherthanunderestimatedthe
effectiveness of monitoring.
Given the lack of clear quantitative data about the
effectiveness of different blood pressure monitoring
strategiesitisperhapsunsurprisingthatcurrenthyper-
tension guidelines pay little attention to monitoring of
patients after the start of treatment.
16172122 While the
absence of evidence precludes the recommendation
of specific follow-up regimens, guidelines could help
clinicians to better interpret the meaning of observed
increases in blood pressure. For example, if clinicians
and patients can be provided with information about
the probability that an observed rise is a true rise it
would help them to make better decisions about man-
agementandavoida cycleofunnecessaryadjustments
to treatment and undesirable fluctuations in blood
pressure. Such a “ping pong” effect has been observed
with the adjustment of warfarin treatment in response
to the international normalised ratio (INR)
423 and
mightbeaproblemformanypeopletakingbloodpres-
sure lowering drugs.
Follow-up visits and blood pressure monitoring are
also used to assess and enhance adherence to treat-
ment. Clearly the observed follow-up blood pressure
is going to be a poor indicator of adherence for the
same reason that it is a poor indicator of response to
treatment,andmonitoringprescriptionrecordsorsen-
sitively questioning patients will probably provide a
better assessment of adherence.
24
Conclusion
We have shown that the probability of correctly iden-
tifying true increases in blood pressure of moderate
magnitude using a typical monitoring regimen is
poor, with a large proportion of observed increases in
blood pressure being false positives. Monitoring at
shortertimeintervalsincreasestheprobabilityofiden-
tifying false positive increases in blood pressure attri-
butabletoshorttermwithinpersonvariabilityofblood
pressure. Longer intervals between measurements
increase the probability that an observed increase in
blood pressure is real, but the capacity of monitoring
to distinguish true increases in blood pressure is poor
even if monitoring is left for several years. Clinicians
need better information about the value of different
monitoringstrategies,andfutureevidencebasedmon-
itoring guidelines would be invaluable.
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